Mologists
| MOLOGEN AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | DE000A2LQ900 |
| Seat |
Berlin , Germany
|
| management | Stefan M. Manth ( CEO ) |
| Number of employees | 50 |
| sales | 3.05 million euros (2018) |
| Branch | Pharmaceutical research |
| Website | www.mologen.com |
| As of December 31, 2018 | |
The MOLOGEN AG is a in the biotechnology and biopharmaceutical internationally active company that specializes in the research and clinical development of innovative drugs in the areas of oncology and infectious diseases has specialized. The main drug candidate lefitolimod is currently being tested in the cancer and HIV / AIDS indications in various clinical and preclinical studies. Using patented technologies and product developments, the company develops DNA-based drugs and researches cell-based therapies . Since June 2009 the shares of Mologen AG have been traded in the Prime Standard of the Frankfurt Stock Exchange. On February 1, 2020, the Charlottenburg District Court opened insolvency proceedings against Mologen AG due to insolvency and over-indebtedness.
history
The company was founded by Burghardt Wittig as a spin-off from the Free University of Berlin in 1998 . The shares of Mologen AG have also been listed on the Frankfurt Stock Exchange since 1998.
Individual evidence
- ↑ a b Annual Report 2018. In: www.mologen.com. Retrieved August 26, 2019 .
- ↑ Mologen: Insolvency proceedings opened. In: boerse.ard.de. Retrieved February 3, 2020 .
- ↑ Partnership in personal union. Retrieved August 14, 2019 .